US · IMDX
Insight Molecular Diagnostics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Nashville, TN 92618
- Website
- imdxinc.com
Price · as of 2024-12-31
$4.18
Market cap 172.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $19.72 | +371.77% |
| Intrinsic Value(DCF) | $1.56 | -62.68% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $121.00 | ||||
| 2016 | $101.00 | ||||
| 2017 | $41.00 | ||||
| 2018 | $67.80 | ||||
| 2019 | $45.80 | ||||
| 2020 | $96.00 | ||||
| 2021 | $25.80 | $16.18 | $0.00 | $0.00 | $0.00 |
| 2022 | $6.86 | $6.74 | $1.91 | $0.00 | $602.92 |
| 2023 | $3.00 | $73.29 | $0.00 | $0.00 | $0.00 |
| 2024 | $3.90 | $19.72 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Insight Molecular Diagnostics Inc.'s (IMDX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $19.72
- Current price
- $4.18
- AI upside
- +371.77%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.56
-62.68% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMDX | Insight Molecular Diagnos… | $4.18 | 172.27M | +372% | -63% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| CCCC | C4 Therapeutics, Inc. | $2.70 | 192.18M | +704% | -21% | — | — | -2.50 | 1.02 | 7.31 | -0.72 | — | 1.02 | 77.81% | -290.68% | -292.08% | -44.44% | -199.27% | -29.63% | 0.23 | — | 7.81 | 7.60 | 0.14 | -1645.00% | 102.00% | 5198.00% | -37.79% | -2.99 | -189.38% | 0.00% | 0.00% | 9.54% | -0.71 | -0.75 | 2.06 | -1.45 |
| CDXS | Codexis, Inc. | $1.01 | 91.23M | +2,411% | +12% | — | +481% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| IVVD | Invivyd, Inc. | $1.69 | 224.31M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
About Insight Molecular Diagnostics Inc.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
- CEO
- Joshua Riggs
- Employees
- 46
- Beta
- 1.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.56 ÷ $4.18) − 1 = -62.68% (DCF, example).